The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).
D. Cella
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
B. Escudier
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - AVEO; Bayer; Bayer; GlaxoSmithKline; Pfizer; Roche
B. I. Rini
Consultant or Advisory Role - AVEO; GlaxoSmithKline; Pfizer
Research Funding - GlaxoSmithKline; Pfizer
C. Chen
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
H. Bhattacharyya
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
J. C. Tarazi
Employment or Leadership Position - Pfizer
B. Rosbrook
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
S. Kim
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
R. J. Motzer
Research Funding - Pfizer